Autoantibodies in lung transplantation

Area of Science:

• Immunology
• Transplantation Science
• Pulmonology

Background:

• Chronic lung allograft dysfunction (CLAD) is a primary cause of long-term graft loss and poor survival after lung transplantation.
• CLAD encompasses bronchiolitis obliterans syndrome and restrictive allograft syndrome, significantly impacting patient outcomes compared to other solid organ transplants.
• Despite increasing lung transplant numbers, effective therapies are limited by an incomplete understanding of CLAD's multifactorial immunoregulatory mechanisms.

Purpose of the Study:

• To review current research on the mechanisms driving chronic lung allograft dysfunction.
• To emphasize the role of immune responses to lung-associated self-antigens (autoimmunity) in CLAD development.
• To highlight emerging therapeutic strategies, such as targeting exosome release, for combating CLAD.

Main Methods:

• Review of recent scientific literature and ongoing research on CLAD.
• Analysis of factors contributing to CLAD, including donor characteristics, inflammation, infection, and allo-/autoimmunity.
• Examination of novel mechanisms like stress-induced exosome release in chronic rejection.

Main Results:

• CLAD pathogenesis is multifactorial, involving a complex interplay of donor factors, early inflammation, infections, and allo- and autoimmunity.
• Stress-induced exosome release from the allograft is identified as a potential underlying mechanism in chronic rejection.
• Autoimmunity directed at donor antigens is increasingly recognized as a significant contributor to CLAD.

Conclusions:

• A comprehensive understanding of CLAD's immunoregulatory pathways is crucial for advancing lung transplant outcomes.
• Targeting autoimmune responses and novel mechanisms like exosome release may offer future therapeutic avenues.
• Individualized treatment strategies are needed to effectively combat chronic lung allograft dysfunction.